PUBLISHER: The Business Research Company | PRODUCT CODE: 1427744
PUBLISHER: The Business Research Company | PRODUCT CODE: 1427744
Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2024
Chemotherapy Induced Peripheral Neuropathy (CIPN) encompasses a range of symptoms and complications arising from specific chemotherapy drugs utilized in cancer treatment. It represents a form of peripheral neuropathy, involving impairment or dysfunction of the nerves connecting the brain and spinal cord to the body.
The primary drug categories for CIPN treatment include nerve protective therapy, anti-inflammatory therapy, neurotransmitter-based therapy, antioxidants, and others. Nerve protective therapy aims to preserve nerve health and function, crucial in managing chemotherapy-induced peripheral neuropathy for symptom relief. Treatment modalities encompass medications, therapies, and other interventions, with both branded and generic drugs available. These CIPN treatment drugs are distributed through hospital pharmacies, retail outlets, online platforms, and other channels, catering to end-users such as hospitals, research institutes, and specialty clinics.
The chemotherapy induced peripheral neuropathy treatment market research report is one of a series of new reports from The Business Research Company that provides chemotherapy induced peripheral neuropathy treatment market statistics, including the chemotherapy induced peripheral neuropathy treatment industry's global market size, regional shares, competitors with an chemotherapy induced peripheral neuropathy treatment market share, detailed chemotherapy induced peripheral neuropathy treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the chemotherapy induced peripheral neuropathy treatment industry. This chemotherapy induced peripheral neuropathy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The chemotherapy induced peripheral neuropathy treatment market size has grown strongly in recent years. It will grow from $1.54 billion in 2023 to $1.65 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth observed in the historical period can be attributed to advancements in chemotherapy, expansion in cancer treatment options, limited alternatives for treatment, a rise in cancer incidences, and progress in neurological research.
The chemotherapy induced peripheral neuropathy treatment market size is expected to see strong growth in the next few years. It will grow to $2.25 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The anticipated growth in the forecast period can be ascribed to the development of targeted therapies, the emergence of neuroprotective agents, the implementation of integrated care pathways, adoption of patient-centered care models, and regulatory support. Key trends in the forecast period encompass innovations in drug formulations, the integration of non-pharmacological interventions, the introduction of neuroplasticity-based therapies, enhanced support for long-term survivorship, and the incorporation of cognitive behavioral therapies.
The growth trajectory of the chemotherapy-induced peripheral neuropathy treatment market is anticipated to be driven by the increasing prevalence of cancer. Cancer, characterized by the unregulated proliferation and dissemination of abnormal cells within the body, often necessitates chemotherapy treatment. However, one of the potential side effects of certain chemotherapy drugs is chemotherapy-induced peripheral neuropathy (CIPN). The rising incidence of cancer cases globally is expected to contribute significantly to the expansion of the chemotherapy-induced peripheral neuropathy treatment market. For instance, a report by the American Cancer Society in January 2023 revealed an increase in newly diagnosed cases of liver cancer in females in the United States, rising from 12,660 cases in 2022 to 13,230 cases in 2023. This escalation in cancer cases acts as a catalyst propelling the growth of the chemotherapy-induced peripheral neuropathy treatment market.
The growth of the chemotherapy-induced peripheral neuropathy treatment market is being fueled by an upsurge in healthcare spending. Healthcare spending, denoting the total financial resources allocated to the healthcare sector within a specific region or country, plays a pivotal role in supporting treatments for chemotherapy-induced peripheral neuropathy (CIPN). This allocation aims to mitigate and manage the adverse neurological effects induced by certain cancer treatments, ensuring the well-being of patients undergoing and recovering from chemotherapy. For instance, data from the American Medical Association in March 2023 indicated a 2.7% increase in health spending in the United States in 2021, reaching $4.3 trillion or $12,914 per capita. This surge in healthcare expenditure serves as a driving force behind the growth of the chemotherapy-induced peripheral neuropathy treatment market moving forward.
Product innovation emerges as a prominent trend in the chemotherapy-induced peripheral neuropathy treatment market, with major market players prioritizing the development of novel products to enhance efficacy and consolidate their market position. Notably, in March 2023, AlgoTx, a clinical-stage company specializing in complex pain management, announced the FDA's approval of their Investigational New Drug Application (IND) for ATX01, a Phase 2 first-in-class candidate designed for individuals with erythromelalgia. The ATX01 for the Pain of Chemotherapy (ACT) study targeting chemotherapy-induced peripheral neuropathy (CIPN) has commenced randomized patient enrollment. Both programs have secured fast-track designation from the FDA, signifying their potential significance in addressing unmet medical needs.
Technological advancements, particularly the incorporation of quell technology, are a focal point for major companies in the chemotherapy-induced peripheral neuropathy treatment market as they endeavor to fortify their market standing. For instance, in January 2022, NeuroMetrix Inc., a US-based provider of non-invasive medical devices, attained breakthrough device designation from the U.S. Food and Drug Administration (FDA) for the mitigation of moderate to severe symptoms of chemotherapy-induced peripheral neuropathy (CIPN) persisting for at least 6 months post-chemotherapy completion. This designation marks a pivotal milestone for NeuroMetrix's efforts to introduce Quell technology to alleviate the distressing effects experienced by individuals grappling with CIPN.
In September 2021, Novaremed AG, a Swiss biopharmaceutical company, successfully acquired Metys Pharmaceuticals AG in a deal of undisclosed value. This strategic acquisition marks a significant expansion for Novaremed AG as it broadens its pipeline to encompass a broader range of neuropathic pain indications. With the incorporation of Metys Pharmaceuticals, Novaremed AG extends its focus beyond painful diabetic peripheral neuropathy (PDPN) to include chemotherapy-induced peripheral neuropathy (CIPN). Metys Pharmaceuticals AG, also based in Switzerland, is recognized for its dedication to the development and commercialization of innovative therapies targeting various medical conditions.
Major companies operating in the chemotherapy induced peripheral neuropathy treatment market report are Sanofi SA, Bristol Myers Squibb, Abbott Laboratories, Takeda Pharmaceutical Company, Amgen Inc., Asahi Kasei Pharma Corporation, Toray Industries , Vertex Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., BioMerieux SA, Jazz Pharmaceuticals Inc., WEX Pharmaceuticals Inc., Quidel Corporation, Laboratories Dr. Esteve S.A. (ESTEVE), Genentech Inc., MediciNova Inc., ChromaDex Corp, WinSanTor Inc., Solasia Pharma K.K., NeuroMetrix Inc., Nemus Bioscience Inc., Aphios Corporation, Kineta Inc., DARA BioSciences Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., Krenitsky Pharmaceuticals Inc.
North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2023. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in the chemotherapy induced peripheral neuropathy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the chemotherapy induced peripheral neuropathy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The chemotherapy induced peripheral neuropathy treatment market consists of sales of pharmaceutical drugs prescribed to alleviate chemotherapy-induced peripheral neuropathy symptoms. These drugs include pain relievers, antidepressants, anticonvulsants, and topical creams. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on chemotherapy induced peripheral neuropathy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for chemotherapy induced peripheral neuropathy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chemotherapy induced peripheral neuropathy treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of covid 19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
- 1) By Drug Class: Nerve Protective Therapy; Anti-Inflammatory Therapy; Neurotransmitter Based Therapy; Antioxidant; Other Drug Classes
- 2) By Treatment: Medication; Therapy; Other Treatments
- 3) By Drug Type: Branded; Generic
- 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Other Distribution Channels
- 5) By End-User: Hospitals; Research Institutes; Specialty Clinics
- Companies Mentioned: Sanofi SA; Bristol Myers Squibb; Abbott Laboratories; Takeda Pharmaceutical Company; Amgen Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Chemotherapy Induced Peripheral Neuropathy Treatment Market Characteristics
3. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends And Strategies
4. Chemotherapy Induced Peripheral Neuropathy Treatment Market - Macro Economic Scenario
- 4.1. Impact Of High Inflation On The Market
- 4.2. Ukraine-Russia War Impact On The Market
- 4.3. COVID-19 Impact On The Market
5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Growth
- 5.1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
- 5.2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
- 5.3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)
6. Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation
- 6.1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Nerve Protective Therapy
- Anti-Inflammatory Therapy
- Neurotransmitter Based Therapy
- Antioxidant
- Other Drug Classes
- 6.2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Medication
- Therapy
- Other Treatments
- 6.3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Branded
- Generic
- 6.4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Other Distribution Channels
- 6.5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Hospitals
- Research Institutes
- Specialty Clinics
7. Chemotherapy Induced Peripheral Neuropathy Treatment Market Regional And Country Analysis
- 7.1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 7.2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 8.1. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
- Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 8.3. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 8.4. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 9.1. China Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
- 9.2. China Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
- 9.3. China Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
- 9.4. China Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 10.1. India Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 10.2. India Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 10.3. India Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 11.1. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
- 11.2. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 11.3. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 11.4. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 12.1. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 12.2. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 12.3. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 13.1. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 13.2. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 13.3. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 14.1. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
- 14.2. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 14.3. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 14.4. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 15.1. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
- 15.2. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 15.3. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 15.4. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 16.1. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 16.2. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 16.3. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 17.1. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 17.2. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 17.3. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 18.1. France Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 18.2. France Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 18.3. France Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 19.1. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 19.2. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 19.3. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 20.1. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 20.2. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 20.3. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 21.1. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
- 21.2. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 21.3. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 21.4. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 22.1. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 22.2. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 22.3. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 23.1. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
- 23.2. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 23.3. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 23.4. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 24.1. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
- 24.2. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 24.3. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 24.4. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 25.1. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
- 25.2. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 25.3. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 25.4. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 26.1. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
- 26.2. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 26.3. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 26.4. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 27.1. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 27.2. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 27.3. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 28.1. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
- 28.2. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 28.3. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 28.4. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market
- 29.1. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
- 29.2. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 29.3. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 29.4. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Landscape And Company Profiles
- 30.1. Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Landscape
- 30.2. Chemotherapy Induced Peripheral Neuropathy Treatment Market Company Profiles
- 30.2.1. Sanofi SA
- 30.2.1.1. Overview
- 30.2.1.2. Products and Services
- 30.2.1.3. Strategy
- 30.2.1.4. Financial Performance
- 30.2.2. Bristol Myers Squibb
- 30.2.2.1. Overview
- 30.2.2.2. Products and Services
- 30.2.2.3. Strategy
- 30.2.2.4. Financial Performance
- 30.2.3. Abbott Laboratories
- 30.2.3.1. Overview
- 30.2.3.2. Products and Services
- 30.2.3.3. Strategy
- 30.2.3.4. Financial Performance
- 30.2.4. Takeda Pharmaceutical Company
- 30.2.4.1. Overview
- 30.2.4.2. Products and Services
- 30.2.4.3. Strategy
- 30.2.4.4. Financial Performance
- 30.2.5. Amgen Inc.
- 30.2.5.1. Overview
- 30.2.5.2. Products and Services
- 30.2.5.3. Strategy
- 30.2.5.4. Financial Performance
- 30.2.1. Sanofi SA
31. Chemotherapy Induced Peripheral Neuropathy Treatment Market Other Major And Innovative Companies
- 31.1. Asahi Kasei Pharma Corporation
- 31.2. Toray Industries
- 31.3. Vertex Pharmaceuticals Inc.
- 31.4. Alexion Pharmaceuticals Inc.
- 31.5. BioMerieux SA
- 31.6. Jazz Pharmaceuticals Inc.
- 31.7. WEX Pharmaceuticals Inc.
- 31.8. Quidel Corporation
- 31.9. Laboratories Dr. Esteve S.A. (ESTEVE)
- 31.10. Genentech Inc.
- 31.11. MediciNova Inc.
- 31.12. ChromaDex Corp
- 31.13. WinSanTor Inc.
- 31.14. Solasia Pharma K.K.
- 31.15. NeuroMetrix Inc.
32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Benchmarking
33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Chemotherapy Induced Peripheral Neuropathy Treatment Market
35. Chemotherapy Induced Peripheral Neuropathy Treatment Market Future Outlook and Potential Analysis
- 35.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2028 - Countries Offering Most New Opportunities
- 35.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2028 - Segments Offering Most New Opportunities
- 35.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
